These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 36152636)

  • 1. Faecal microbiota transplantation for first or second Clostridioides difficile infection (EarlyFMT): a randomised, double-blind, placebo-controlled trial.
    Baunwall SMD; Andreasen SE; Hansen MM; Kelsen J; Høyer KL; Rågård N; Eriksen LL; Støy S; Rubak T; Damsgaard EMS; Mikkelsen S; Erikstrup C; Dahlerup JF; Hvas CL
    Lancet Gastroenterol Hepatol; 2022 Dec; 7(12):1083-1091. PubMed ID: 36152636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
    Khanna S; Assi M; Lee C; Yoho D; Louie T; Knapple W; Aguilar H; Garcia-Diaz J; Wang GP; Berry SM; Marion J; Su X; Braun T; Bancke L; Feuerstadt P
    Drugs; 2022 Oct; 82(15):1527-1538. PubMed ID: 36287379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Faecal microbiota transplantation for
    Terveer EM; Vendrik KE; Ooijevaar RE; Lingen EV; Boeije-Koppenol E; Nood EV; Goorhuis A; Bauer MP; van Beurden YH; Dijkgraaf MG; Mulder CJ; Vandenbroucke-Grauls CM; Seegers JF; van Prehn J; Verspaget HW; Kuijper EJ; Keller JJ
    United European Gastroenterol J; 2020 Dec; 8(10):1236-1247. PubMed ID: 32990503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial.
    Paramsothy S; Kamm MA; Kaakoush NO; Walsh AJ; van den Bogaerde J; Samuel D; Leong RWL; Connor S; Ng W; Paramsothy R; Xuan W; Lin E; Mitchell HM; Borody TJ
    Lancet; 2017 Mar; 389(10075):1218-1228. PubMed ID: 28214091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial.
    Aroniadis OC; Brandt LJ; Oneto C; Feuerstadt P; Sherman A; Wolkoff AW; Kassam Z; Sadovsky RG; Elliott RJ; Budree S; Kim M; Keller MJ
    Lancet Gastroenterol Hepatol; 2019 Sep; 4(9):675-685. PubMed ID: 31326345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection.
    Cammarota G; Masucci L; Ianiro G; Bibbò S; Dinoi G; Costamagna G; Sanguinetti M; Gasbarrini A
    Aliment Pharmacol Ther; 2015 May; 41(9):835-43. PubMed ID: 25728808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials.
    Gerding DN; Cornely OA; Grill S; Kracker H; Marrast AC; Nord CE; Talbot GH; Buitrago M; Gheorghe Diaconescu I; Murta de Oliveira C; Preotescu L; Pullman J; Louie TJ; Wilcox MH
    Lancet Infect Dis; 2019 Mar; 19(3):265-274. PubMed ID: 30709665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, immunogenicity, and efficacy of a Clostridioides difficile toxoid vaccine candidate: a phase 3 multicentre, observer-blind, randomised, controlled trial.
    de Bruyn G; Gordon DL; Steiner T; Tambyah P; Cosgrove C; Martens M; Bassily E; Chan ES; Patel D; Chen J; Torre-Cisneros J; Fernando De Magalhães Francesconi C; Gesser R; Jeanfreau R; Launay O; Laot T; Morfin-Otero R; Oviedo-Orta E; Park YS; Piazza FM; Rehm C; Rivas E; Self S; Gurunathan S
    Lancet Infect Dis; 2021 Feb; 21(2):252-262. PubMed ID: 32946836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.
    Cornely OA; Crook DW; Esposito R; Poirier A; Somero MS; Weiss K; Sears P; Gorbach S;
    Lancet Infect Dis; 2012 Apr; 12(4):281-9. PubMed ID: 22321770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Fecal Microbiota Transplantation on Recurrence in Multiply Recurrent Clostridium difficile Infection: A Randomized Trial.
    Kelly CR; Khoruts A; Staley C; Sadowsky MJ; Abd M; Alani M; Bakow B; Curran P; McKenney J; Tisch A; Reinert SE; Machan JT; Brandt LJ
    Ann Intern Med; 2016 Nov; 165(9):609-616. PubMed ID: 27547925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infection-single versus multiple infusions.
    Ianiro G; Masucci L; Quaranta G; Simonelli C; Lopetuso LR; Sanguinetti M; Gasbarrini A; Cammarota G
    Aliment Pharmacol Ther; 2018 Jul; 48(2):152-159. PubMed ID: 29851107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial.
    Kokai-Kun JF; Roberts T; Coughlin O; Le C; Whalen H; Stevenson R; Wacher VJ; Sliman J
    Lancet Infect Dis; 2019 May; 19(5):487-496. PubMed ID: 30885591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of a microbial ecosystem therapeutic (MET-2) on recurrent Clostridioides difficile infection: a phase 1, open-label, single-group trial.
    Kao D; Wong K; Franz R; Cochrane K; Sherriff K; Chui L; Lloyd C; Roach B; Bai AD; Petrof EO; Allen-Vercoe E
    Lancet Gastroenterol Hepatol; 2021 Apr; 6(4):282-291. PubMed ID: 33631102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fecal Microbiota Transplantation Is Superior to Fidaxomicin for Treatment of Recurrent Clostridium difficile Infection.
    Hvas CL; Dahl Jørgensen SM; Jørgensen SP; Storgaard M; Lemming L; Hansen MM; Erikstrup C; Dahlerup JF
    Gastroenterology; 2019 Apr; 156(5):1324-1332.e3. PubMed ID: 30610862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Faecal microbiota transplantation for Clostridium difficile-associated diarrhoea: a systematic review of randomised controlled trials.
    Moayyedi P; Yuan Y; Baharith H; Ford AC
    Med J Aust; 2017 Aug; 207(4):166-172. PubMed ID: 28814204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial.
    Haifer C; Paramsothy S; Kaakoush NO; Saikal A; Ghaly S; Yang T; Luu LDW; Borody TJ; Leong RW
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):141-151. PubMed ID: 34863330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Faecal microbiota transplantation in the treatment of recurrent intestinal Clostridioides difficile infection - a ten-year single-center experience.
    Pipek B; Valentová H; Fojtík P; Urban O
    Cas Lek Cesk; 2022; 161(3-4):126-130. PubMed ID: 36100450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study.
    Vickers RJ; Tillotson GS; Nathan R; Hazan S; Pullman J; Lucasti C; Deck K; Yacyshyn B; Maliakkal B; Pesant Y; Tejura B; Roblin D; Gerding DN; Wilcox MH;
    Lancet Infect Dis; 2017 Jul; 17(7):735-744. PubMed ID: 28461207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial.
    Johnsen PH; Hilpüsch F; Cavanagh JP; Leikanger IS; Kolstad C; Valle PC; Goll R
    Lancet Gastroenterol Hepatol; 2018 Jan; 3(1):17-24. PubMed ID: 29100842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SER-109, an Oral Microbiome Therapy for Recurrent
    Feuerstadt P; Louie TJ; Lashner B; Wang EEL; Diao L; Bryant JA; Sims M; Kraft CS; Cohen SH; Berenson CS; Korman LY; Ford CB; Litcofsky KD; Lombardo MJ; Wortman JR; Wu H; Auniņš JG; McChalicher CWJ; Winkler JA; McGovern BH; Trucksis M; Henn MR; von Moltke L
    N Engl J Med; 2022 Jan; 386(3):220-229. PubMed ID: 35045228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.